Anti-neoplastic properties of hydralazine in prostate cancer by Pinho dos Santos Graça, Maria Inês et al.
Oncotarget5950www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 15
Anti-neoplastic properties of hydralazine in prostate cancer
Inês Graça1,4, Elsa J Sousa1, Pedro Costa-Pinheiro1, Filipa Q Vieira1,4, Jorge Torres-
Ferreira1,2, Maria Gabriela Martins 3, Rui Henrique1,2,5, Carmen Jerónimo1,5
1 Cancer Biology & Epigenetics Group, Research Center of the Portuguese Oncology Institute-Porto,
2 Department of Pathology, Portuguese Oncology Institute-Porto,
3 Department of Hematology - Laboratory of Flow Cytometry, Portuguese Oncology Institute-Porto,
4 Departments of School of Allied Health Sciences ESTSP, Polytechnic of Porto, 
5 Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto
Correspondence to: Carmen Jerónimo, email: carmenjeronimo@ipoporto.min-saude.pt
Keywords: Prostate Cancer, Hydralazine, DNA methyltransferases, Androgen Receptor
Received: February 14, 2014 Accepted: April 16, 2014 Published: April 17, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT:
Prostate cancer (PCa) is a major cause of cancer-related morbidity and mortality 
worldwide. Although early disease is often efficiently managed therapeutically, 
available options for advanced disease are mostly ineffective. Aberrant DNA 
methylation associated with gene-silencing of cancer-related genes is a common 
feature of PCa. Therefore, DNA methylation inhibitors might constitute an attractive 
alternative therapy. Herein, we evaluated the anti-cancer properties of hydralazine, 
a non-nucleoside DNA methyltransferases (DNMT) inhibitor, in PCa cell lines. In vitro 
assays showed that hydralazine exposure led to a significant dose and time dependent 
growth inhibition, increased apoptotic rate and decreased invasiveness. Furthermore, 
it also induced cell cycle arrest and DNA damage. These phenotypic effects were 
particularly prominent in DU145 cells. Following hydralazine exposure, decreased 
levels of DNMT1, DNMT3a and DNMT3b mRNA and DNMT1 protein were depicted. 
Moreover, a significant decrease in GSTP1, BCL2 and CCND2 promoter methylation 
levels, with concomitant transcript re-expression, was also observed. Interestingly, 
hydralazine restored androgen receptor expression, with upregulation of its target 
p21 in DU145 cell line. Protein array analysis suggested that blockage of EGF receptor 
signaling pathway is likely to be the main mechanism of hydralazine action in DU145 
cells. Our data demonstrate that hydralazine attenuated the malignant phenotype of 
PCa cells, and might constitute a useful therapeutic tool. 
INTRODUCTION 
Prostate cancer (PCa) is the second most common 
malignant neoplasm diagnosed in men and the sixth 
leading cause of cancer-related mortality worldwide [1]. 
Although most early-diagnosed patients have optimal 
survival rates after treatment with prostatectomy or 
radiotherapy, treatment of advanced disease is mainly 
ineffective and remains a clinical challenge [2]. Androgen-
deprivation therapy, by pharmacological or surgical 
castration, is widely used for locally advanced and 
systemically spread PCa. However, most patients that 
initially respond to this type of therapy have a median 
time for progression to castration-resistant disease of 
only 18-30 months [3]. Therefore, investigation of new 
and more effective therapeutic strategies is urgently 
needed for this important subset of PCa patients. 
Alterations in DNA methylation are early events in human 
carcinogenesis, including PCa, which are conserved 
during cancer progression [4]. Aberrant methylation 
of CpG dinucleotides in gene promoter regions is 
associated with transcriptional repression, not only of 
tumor-suppressor genes, but also of genes with important 
regulatory functions [5, 6]. DNA methyltransferases 
(DNMTs) are a group of enzymes responsible for the 
establishment and maintenance of methylation patterns. 
Because epigenetic alterations, contrarily to genetic 
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modifications, are reversible, inhibition of DNMTs 
might have the ability to overturn tumor cell phenotype, 
constituting an attractive therapeutic target [7]. So far 
only two nucleoside analogues, 5-azacytidine (5-Aza-
CR) and 5-aza-2´-deoxycytidine (5-Aza-CdR) have been 
approved by Food and Drug Administration (FDA) for 
clinical use, specifically in myelodysplastic syndrome 
[8]. Nevertheless, their clinical effectiveness is not 
entirely dependent on their DNA methylation inhibitory 
activity and its efficacy in solid tumors is yet to be fully 
demonstrated [9]. Indeed, 5-Aza-CdR was shown to 
have modest clinical activity against castration-resistant 
PCa in a phase II clinical trial [10]. Due to the toxicity 
of nucleoside analogues, efforts have been made to 
develop and test non-nucleoside compounds that target 
DNMTs, which are not incorporated in the DNA and/or 
RNA, for solid tumors. Recently, we reported RG108 
as an effective tumor growth suppressor in PCa cell 
lines. However, this drug is substantially more effective 
in androgen-responsive than in castration-resistant 
cell lines [11]. Among non-nucleoside analogues, 
hydralazine, a potent arterial vasodilator approved by 
FDA for treatment of severe hypertension, heart failure 
and hypertension in pregnancy, has been described as a 
weak non-nucleoside DNA methylation inhibitor [12-14]. 
Furthermore, this drug has been shown to demethylate 
and reactivate the expression of several cancer-related 
genes and its activity is synergistic with that of the histone 
deacetylase inhibitor (HDACi) valproic acid, either in 
vitro or in vivo [15, 16]. In patients carrying solid tumors 
refractory to conventional treatment, clinical trials have 
been conducted in which those epigenetic drugs were 
combined with conventional therapy. It was shown that 
this regimen was not only well tolerated, but, importantly, 
it overcome tumors’ chemotherapy resistance and induced 
radiosensitivity [17, 18]. To the best of our knowledge, 
the antineoplastic effect of hydralazine in PCa has not 
been previously investigated. Therefore, in the context 
of a broader research project intended to determine the 
therapeutic efficacy of compounds targeting epigenetic 
alterations of PCa cells, we aimed at evaluating the impact 
of hydralazine as a PCa growth inhibitor as well as its 
effect on DNA demethylation activity and consequent 
reactivation of genes known to be epigenetically silenced 
in this neoplasm. Additionally, we investigated the cellular 
pathway through which hydralazine exerts its growth-
inhibitory effect. We found that hydralazine was able to 
reverse PCa cell phenotype, decrease DNMTs expression 
and gene promoter methylation with concomitant 
expression’s restoration of silenced genes involved in 
prostate carcinogenesis. Moreover, this compound was 
capable of restoring androgen receptor (AR) expression in 
DU145 cell line. Importantly, we found that hydralazine 
growth-inhibitory effects occur in cell cycle and EGF 
receptor signaling pathway inhibition.
RESULTS
Hydralazine reverts PCa cells malignant 
phenotype
The half-maximal effective concentration (EC50) of 
hydralazine was calculated in two PCa cell lines (LNCaP 
and DU145) after 72 hours of drug exposure. The drug 
displayed an EC50 of 63 μM in LNCaP and 30 μM in 
DU145 (Supplementary Figure 1). To investigate the 
effects of hydralazine on the malignant phenotype of PCa, 
four human PCa cell lines (LNCaP, 22Rv1, DU145, and 
PC-3) were exposed to two different concentrations of 
this drug (20 and 40 μM) or to the vehicle (PBS) during 
14 days, as previously described for RG108 [11]. Cell 
viability was evaluated at days 0, 1, 2, 3, 7, 10, and 14. 
Exposure to hydralazine markedly reduced cell viability, 
especially at 40 μM concentration (Fig. 1A). Remarkably, 
a significant decrease in the number of viable cells was 
observed at the day 2, with a more pronounced effect 
after 14 days of exposure to both drug concentrations in 
LNCaP, whereas for 22Rv1 a less impressive effect was 
observed, even after exposure to the highest concentration. 
PC-3 treated cells also depicted a slight reduction at 
the end of day 3 through day 10. Interestingly, DU145 
was the most sensitive cell line, since inhibition of cell 
viability was achieved in all tested days for both drug 
concentrations. These results were corroborated by 
mRNA expression levels of two genes involved in cell 
proliferation. Due to its low viability rate, this cell line 
was evaluated after three days of drug exposure. Indeed, 
a significant induction of CDKN1A and decrease of Ki67 
mRNA levels was observed in hydralazine treated cells 
compared to the respective vehicle (Fig. 1B). Additionally, 
alterations in cell cycle distribution were evaluated and 
a significant cell cycle arrest was observed at G0/G1 for 
all cell lines, except for LNCaP in which the arrest was 
observed at S phase (Fig. 1C). A significant increase in 
apoptosis was depicted for all cell lines with both drug 
concentrations (Fig. 1D). To confirm the activation of the 
apoptotic pathway, CASP8, CASP9, and CASP3 mRNA 
levels were also evaluated. A statistically significant 
increase in transcript levels of CASP3 and CASP8 was 
found for DU145, and LNCaP, respectively, whereas 
CASP9 expression levels were increased in LNCaP and 
22Rv1 cells (Fig. 1E). Furthermore, a significant increase 
in Sub-G1 cell population was observed for three of the 
cell lines [22Rv1, DU145 and PC-3 (Fig. 1C)]. The two 
best responsive PCa cell lines, DU145 and LNCaP, also 
showed a significant decrease in invasion ability after 48 
hours exposure to hydralazine (Fig. 1F). 
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Figure 1: Phenotypic effects induced by hydralazine in PCa cell lines. (A) Cell viability in LNCaP, 22Rv1, PC-3 and DU145, 
exposed to hydralazine and drug vehicle, at days 0, 1, 2, 3,7,10, and 14, measured by MTT assay. (a) Statistically significant differences 
were observed between vehicle and 20 µM hydralazine, and (b) vehicle and 40 µM hydralazine. (B) mRNA expression of Ki67 and 
CDKN1A in LNCaP, 22Rv1 and PC-3 after 14 days and DU145 after 3 days of exposure to hydralazine. (C) Cell cycle evaluation after 
14 days of hydralazine exposure in LNCaP, 22Rv1 and PC-3 and three days of hydralazine exposure in DU145. (D) Effect of hydralazine 
exposure in early apoptosis of PCa cell lines, measured at days 3 and 7 in all PCa cell lines and at day 14 in LNCaP, 22Rv1 and PC-3, 
with a phosphatidylserine based assay. (E) CASP3, CASP8 and CASP9 mRNA expression in LNCaP, 22Rv1 and PC-3 after 14 days and 
DU145 after 3 days of exposure to hydralazine. (F) Effect of hydralazine exposure on the invasion potential of LNCaP and DU145 (upper 
– immunofluorescence images of vehicle and hydralazine exposed cells, counterstained with DAPI; down – graphic representation of the 
total number of invasive cells). All data are presented as mean of three independent experiments ± s.d.
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Hydralazine disrupts the expression of cell cycle 
genes
A panel of genes representative of critical cellular 
pathways were selected for assessment of expression 
in LNCaP and DU145 (Fig. 2). Globally, cell cycle-
associated genes were upregulated and comparative 
analysis between the most altered genes in two cell lines, 
allowed for the identification of five upregulated (CCND2, 
ELL2, BAX, CCND3 and CCNE1) and five downregulated 
(BIRC5, PARP1, CCNB1, BID and TET1) genes.
Hydralazine induce DNA Damage in PCa Cell 
Lines
PCa cells exposed to hydralazine showed significant 
DNA damage compared to those exposed to the vehicle, 
as depicted by the increase in tail length of the comet (Fig. 
3A). Remarkably, an increase in protein expression of 
cleaved PARP1, a protein involved in DNA repair, was 
found in 22RV1 whereas a decrease was displayed by 
LNCaP. No changes in expression of this protein were 
observed in DU145 and PC-3 cells (Fig. 3B).
Hydralazine decreases DNMTs expression and 
leads to demethylation and reactivation of 
silenced genes in human PCa cells
A reduction in mRNA expression for all three 
DNMTs was depicted in DU145 and PC-3 cells. A 
significant decrease in DNMT1 was achieved after 
exposure to 20 µM hydralazine in DNMT3a, after 40 µM 
in DU145 and with both drug concentrations in PC-3; as 
well as for DNMT3b with both concentrations in both cell 
lines. LNCaP only showed decreased levels of DNMT1 
and DNMT3a when exposed to 40 µM hydralazine 
(Fig. 4A). Notably, a reduction in DNMT1 protein 
expression was observed for all tested cell lines (Fig. 
4B). Gene promoter methylation status and expression 
Figure 2: Effects of hydralazine in cellular pathways. Image of deregulated genes after exposure of LNCaP (left) and DU145 
(right) to 20 and 40 µM hydralazine. Induced in gene expression is represented in red, while decreased expression is shown in green. Real-
time RT-PCR values were normalized to three reference genes (18S, TFRC and GUSB). All experiments were performed in triplicate.
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levels of five genes (GSTP1, APC, RARβ2, CCND2 and 
BCL2), previously reported to be silenced by promoter 
hypermethylation in PCa, was evaluated. Both LNCaP 
and 22Rv1 showed a significant decrease in methylation 
levels of GSTP1 with 20 µM whereas only LNCaP 
exhibited similar results with 40 µM (Fig. 4C). Despite 
both cell lines presented a trend for increase GSTP1 
mRNA expression when exposed to 40 µM hydralazine, 
only in LNCaP statistical significance was observed 
(Fig. 4D). DU145 cells did not show significant GSTP1 
promoter methylation. Concerning APC and RARβ2, only 
22Rv1 demonstrated a significant decrease in promoter 
methylation levels (Fig. 4C). Interestingly, significant re-
expression of those genes was only achieved in LNCaP 
and DU145 (Fig. 4D). BCL2 methylation levels were 
reduced in LNCaP and DU145 (Fig. 4C) but mRNA re-
expression was observed following exposure to 40 µM 
hydralazine (Fig. 4D). Although a significant reduction 
in CCND2 methylation was observed only in 22Rv1 and 
DU145 with both drug concentrations (Fig. 4D), gene re-
expression was also achieved in LNCaP (Fig. 4D). 
Hydralazine induces histone acetylation in LNCaP 
and DU145 cell lines
Since hydralazine induced re-expression of CCND2, 
RARβ2 and APC in LNCaP and RARβ2 in DU145, 
without a concomitant significant reduction in DNA 
methylation, and because histone acetylation interplays 
with DNA methylation, the acetylation of Histone 3 
(AcH3) was evaluated by western blot in those two cell 
lines. Interestingly, exposure to both concentrations of 
hydralazine increased AcH3 expression in LNCaP and 
DU145 (Fig. 5). In addition, histone methyltransferase 
G9A expression was also evaluated, but no significant 
differences were found between vehicle and hydralazine 
treated cells (Supplementary Figure 2).
Figure 3: Hydralazine effect on DNA damage. (A) Left - Comet assay immunofluorescence images of vehicle and hydralazine 
exposed cells counterstained with Syber Green and right - graphic representation of mean tail moment. (B) PARP1 protein expression 
analyzed by western blot. Full length PARP1 is represented by a band of 116 kDa and cleaved PARP1 is represented by a 89 kDa band. 
β-Actin was used as a loading control. All data are presented as mean of three independent experiments ± s.d.
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Figure 4: Impact of hydralazine on specific gene methylation of PCa cells. (A) Real-time RT-PCR of mRNA levels of DNMT1, 
DNMT3a and DNMT3b normalized to GUSB in vehicle and drug exposed cells. (B) Western blot analysis of DNMT1 protein expression. 
β-Actin was used as a loading control. (C) Real-time methylation-specific PCR (qMSP) for assessment of GSTP1, APC, RARβ2, CCND2 
and BCL2 methylation levels, normalized to β-Actin. (D) mRNA expression of GSTP1, APC, RARβ2, CCND2 and BCL2, by real-time RT-
PCR, in both hydralazine and vehicle exposed cells. All data are presented as mean of three independent experiments ± s.d.
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Hydralazine restores Androgen receptor 
expression in DU145 cell line
It is widely acknowledged that one of the 
mechanisms of androgen receptor (AR) silencing 
in castration-resistant cell line DU145 is promoter 
hypermethylation [19]. After three days of exposure 
to 40 µM of hydralazine a significant reduction in 
AR methylation levels was observed (Fig. 6A) with 
concomitant AR protein re-expression, at both drug 
concentrations (Fig. 6B). Re-expression was more evident 
when cells were exposed to 20 µM hydralazine. To further 
demonstrate AR activation, an increase in p21 protein 
expression was detected after drug exposure (Fig. 6B), 
which is in accordance with the reported ability of AR to 
upregulate p21 in PCa cell lines [20].
Hydralazine may exert its growth-inhibitory 
effect in DU145 cells by interfering with EGF 
signaling pathway 
Because DU145 showed the largest sensitivity 
to hydralazine, it was chosen to investigate the cellular 
mechanisms and pathways underlying these pronounced 
effects, using a protein array. After drug exposure, 69 
proteins presented altered expression, of which 40 were 
considered downregulated and 29 upregulated (Fig. 
7A). These 69 proteins were then analyzed with DAVID 
(Database for Annotation, Visualization and Integrated 
Discovery) and several cellular networks were identified 
as being altered after drug exposure (Fig. 7B). However, 
EGF receptor signaling pathway (p-value = 1x10-8) scored 
the highest significance value. Therefore, several of the 
identified underexpressed members in array platform were 
further validated (EGFR, EGFR phosphorylated at Y1172, 
Akt1, phosphorylated Akt1 at S473, SRC, phosphorylated 
C-Jun at Thr91 and S73, MEK1 and ERK1/2) by Western 
blot analysis (Fig. 7C). Moreover, EGFR was reported to 
be oncogenic activated by somatic mutations in PCa [21]. 
In order to ascertain if the EGFR pathway was intact in 
PCa cell lines, we sequenced EGFR in LNCaP, 22Rv1, 
DU145 and PC-3 cells for mutational hotspots regions. No 
EGFR mutations were found in any of the four tested PCa 
cell lines.
DISCUSSION
Although most diagnosed PCa remain localized, 
hardly threatening life expectancy, about one third of 
those tumors metastasize to distant organs and eventually 
cause patient death. Median survival for patients with 
localized PCa is more than five years compared with 
one to three years for patients with metastatic disease. 
Although first line therapy for metastatic PCa is either 
pharmacological or surgical castration, most patients 
become androgen refractory within a relatively short 
period of time. Available therapies for castration-resistant 
PCa only aim to reduce symptoms and improve in overall 
survival is only about two months [2]. Therefore, new 
therapeutic options for this disease stage are mandatory. 
Cancer-related gene promoter methylation is an emerging 
molecular marker in PCa and at least 100 genes involved 
in several cellular functions are de novo methylated 
during prostate carcinogenesis [22]. Therefore, DNMTi 
might be a valuable therapeutic tool for PCa. The two 
FDA approved nucleoside DNMTi, however, are of 
limited effectiveness in solid tumors, including PCa [9, 
10]. This might be due to limited incorporation into PCa 
cells, which are much less proliferative, compared to 
hematological malignancies. This might be overcome with 
the use of non-nucleoside DNMTi, which are independent 
of replication for incorporation into DNA.
Herein, we report, for the first time, that hydralazine, 
a non-nucleoside DNMTi, has anti-tumoral effect in PCa 
cells. This compound reduced cell viability and induced 
Figure 5: Effect of hydralazine on histone 3 acetylation 
(AcH3). Western Blot analysis of AcH3, in LNCaP (after 
14 days of drug exposure) and DU145 (after 3 days of drug 
exposure).  β-Actin was used as a loading control.
Figure 6: Reactivation of androgen receptor (AR) 
expression upon exposure to hydralazine. (A) Promoter 
methylation levels of AR in DU145 cell line assessed by real-
time methylation-specific PCR (qMSP) after 3 days of drug 
exposure. AR methylation levels were normalized to β-Actin. 
Data are presented as mean of three independent experiments ± 
s.d. (B) AR and p21 protein expression determined by western 
blot, after 3 days of hydralazine exposure. β-Actin was used as 
loading control.
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cell death by apoptosis in PCa cell lines in a dose and 
time-dependent manner, being 40 µM the best drug 
concentration in all tested cell lines. Similar results were 
observed for human cervical cancer cells when exposed to 
40 µM, resulting in 40 to 50% of cell growth inhibition and 
induction of apoptosis, without affecting normal cells [15]. 
Figure 7: EGF signaling pathway deregulation in DU145 cells after hydralazine exposure. (A) Protein expression heat map 
of DU145exposed to 40 µM hydralazine (red: protein overexpression; green: protein reduced expression. Experiments were performed 
in triplicate. (B) Altered cellular pathways identified by DAVID software. EGF receptor pathway showed the lowest p value (10-8). (C) 
Western Blot validation of disrupted targets of EGF receptor pathway in DU145 cell line upon hydralazine exposure. β-Actin was used as 
loading control
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Importantly, both inhibition of cell viability and apoptosis 
induction were confirmed at molecular level, the former 
by a significant decrease in the cell proliferation marker 
Ki67 and an increase in CDKN1A, a gene that codifies 
p21 a well-known cell cycle inhibitor, and the latter by 
induction of caspases’ expression. Furthermore, our data 
also show that hydralazine induces cell cycle arrest at G0/
G1 in three PCa cell lines, which is in accordance with a 
previous report in bladder cancer [23]. Moreover, LNCaP 
cells also demonstrated cell cycle arrest at S phase after 
hydralazine exposure, similar to human cervical cancer 
cells [15]. Importantly, hydralazine drastically reduced the 
invasive potential of PCa cells, a feature that is particularly 
relevant because metastatic spread is a major cause of PCa 
morbidity and mortality. 
Exposure of PCa cell lines to hydralazine resulted 
in significant induction of DNA damage, accompanied by 
significant PARP-1 decrease in LNCaP cells. Interestingly, 
previous studies have shown that hydralazine exposure 
induced both DNA cleavage and damage [24, 25]. The 
lack of efficient DNA repair is often an advantage for 
cancer therapy (especially radio- and chemotherapy), 
based on the concept of synthetic lethality, which states 
that cancer cells are more proliferative and thus more 
susceptible to induced DNA damage than normal cells. In 
fact, DNA repair is considered a mechanism of cancer-
therapy resistance [26]. Currently, several agents capable 
of inhibiting PARP-1 are under test and those drugs might 
be useful as chemosensitizers for cancer therapy [27]. 
Taking in consideration our results is tempting to speculate 
whether hydralazine might be useful as a chemosensitizer, 
acting in concert with conventional therapeutic strategies.
Remarkably, hydralazine was not only able to 
inhibit DNMT1, 3a and 3b mRNA expression in three 
of the four tested cell lines, but also DNMT1 protein 
expression in all cell lines. Moreover, our data indicate 
that the reduction in DNMT1 expression might not be 
dependent on its regulator and co-factor G9A, since no 
alterations were observed for G9A expression after drug 
exposure. The ability of hydralazine to reduce DNMTs 
expression had already been described in other tumor 
models [28, 29]. Several studies demonstrated that 
DNMT1 is overexpressed in human PCa tissues, compared 
to normal prostate, leading to deleterious inactivation of 
tumor-suppressor genes and might be associated with 
tumor progression and poor prognosis [30]. Therefore, the 
reduction of DNMTs expression might be related with the 
observed reversal of GSTP1, BCL2 and CCND2 promoter 
hypermethylation with concomitant re-expression upon 
hydralazine exposure. Interestingly, hydralazine’s ability 
to demethylate the promoter region of tumor-suppressor 
genes, including GSTP1, RARβ2 and p16, causing its re-
Figure 8: Proposed model for hydralazine disruption of EGF receptor pathway in DU145 cell line. Exposure of PCa cells 
to hydralazine probably leads to demethylation of a critical gene that codifies a protein X that regulates EGFR phosphorylation. The re-
expression of this protein will induce a significant decrease in EGFR phosphorylation and, consequently, in downstream targets, namely, 
SRC, MEK1/2 and Akt. Reduced expression of SRC may cause a decrease in JNK and C-Jun proto-oncogene leading to decreased motility 
and invasion capacity of PCa cells. Moreover, a decrease in MAPK pathway induced by SRC and/or directly via EFGR impairment, could 
explain the decrease in proliferation and cell cycle arrest observed in this cell line after hydralazine exposure. Finally, a decrease in Akt 
expression may lead to cell death and decreased tumor angiogenesis. The disruption of these cancer networks through deregulation EGF 
pathway by hydralazine might be responsible for the attenuation of the malignant phenotype of DU145 cells.
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expression has been documented in several cancers [23, 
29]. Nonetheless, for CCND2, RARβ2 and APC, gene 
re-expression was achieved without significant promoter 
demethylation, in our study. Concerning the AR promoter, 
a significant reduction in methylation levels was only 
observed with the highest concentration of hydralazine, 
although re-expression was already apparent at the lowest 
concentration. These findings further demonstrate that 
epigenetic silencing of cancer-related genes is a complex 
phenomenon, in which other mechanisms, such as histone 
post-translational modifications are also implicated, in 
addition to promoter methylation [22]. Thus, the observed 
increase in AcH3 following hydralazine exposure might 
have contributed to CCND2 and AR re-expression. 
As previously stated, hydralazine restored AR 
mRNA and protein expression in DU145 cells, in which 
AR is silenced due to promoter hypermethylation [19]. 
Similar results were reported for estrogen receptor (ER) 
protein in the ER negative MDA-231 breast cancer 
cell line [23]. Interestingly, AR re-expression has been 
also achieved following chronic exposure (20 days) to 
5-Aza-CR, resulting in a marked decrease of tumor cell 
proliferation and a significant increase of AR and PSA 
protein levels [31]. The lack of AR expression has been 
associated with increased invasive properties, suggesting 
that therapies able to restore its expression receptor may 
reduce tumor dissemination [32]. Therefore, the restoration 
of AR expression by hydralazine might be associated with 
the observed reduction in the invasive potential of DU145 
cells, and could also justify the remarkable decrease in 
cell proliferation by the upregulation of its inhibitor, p21. 
Hence, it is suggested that patients with castration-resistant 
PCa might become more responsive to hormone therapy 
following hydralazine administration, thus slowing PCa 
progression. Remarkably, the combination of 5-Aza-
CdR with the anti-androgen bicalutamide demonstrated 
a synergistic effect, increasing the susceptibility of PCa 
cells to undergo apoptosis and repressing tumor growth 
in xenograft mice [31, 33]. Recently, high expression 
levels of DNMT3a and DNMT3b have been associated 
with bicalutamide resistance and, consequently, with the 
emergence of the castration-resistant phenotype [34]. 
Because hydralazine was shown to decrease all DNMTs 
expression in DU145, a synergistic action between this 
drug and conventional anti-androgenic therapy is likely 
to exist.
DU145 cell line was shown to be highly responsive 
to hydralazine because unlike others cell lines, which 
required 14 days of drug exposure to achieve pronounced 
phenotypic effects, it demonstrated maximal anti-cancer 
effects upon only three days of exposure. Based on the 
analysis of a selected panel of 854 proteins we suggest 
that the remarkable effects of hydralazine on DU145 cells 
are mostly due to disruption of EGF receptor signaling 
pathway. EGFR is overexpressed in PCa and plays an 
important role in cancer cell growth, especially during 
androgen withdrawal [35]. Considering the important 
role of EGFR in prostate carcinogenesis, it has been 
suggested that a general inhibition of this pathway 
could provide therapeutic advantage against metastatic 
PCa [36]. Interestingly, negative regulators of EGFR 
phosphorylation (e.g., Syk) are known to be silenced 
by promoter methylation in PCa [37]. Therefore, we 
postulate that hydralazine may cause demethylation and 
consequent re-expression of those proteins, decreasing 
EGFR phosphorylation and activation. In support of 
this hypothesis, DU145 cell line exposed to hydralazine 
showed downregulation of all major downstream proteins 
in the EGF pathway (Fig. 8). Reduced expression of the 
phosphorylated form of EGFR might justify the decreased 
expression of its direct targets, Src, Akt and MEK1/2. Src 
has been described to be highly expressed in PCa, which 
may lead to JNK and C-Jun activation and, subsequently, 
to an increase in motility and invasion potential of 
PCa cells. Furthermore, it may activate MEK1/2 and, 
consequently, Erk1/2, increasing cell proliferation [38]. 
This MAP kinase pathway can also be directly activated 
by EGFR phosphorylation. Interestingly, the synergism 
between SRC and EGFR in PCa may be associated with 
a more aggressive tumor phenotype [39]. Moreover, Akt 
phosphorylation has been associated with PCa progression 
and it was suggested as an excellent biomarker for 
biochemical recurrence [40]. Importantly, through the 
interaction with EGF pathway, hydralazine may disrupt 
several cancer cell networks: by means of SRC, it may 
lead to a decrease in motility and invasion of tumor cells, 
through AKT, downregulate neoangiogenesis and increase 
apoptosis, and, finally, through, MAP kinase pathway, 
decrease tumor cell proliferation.
Because, hydralazine can maintain gene re-
expression for longer periods of time, it was suggested 
that it has higher demethylase activity and, therefore, more 
effectiveness than 5-aza-CdR [14]. Thus, hydralazine 
might be more attractive from a clinical standpoint because 
to keep tumor-suppressor genes demethylated, cancer 
cells need to be chronically exposed to DNMTi. Because 
5aza-CdR is incorporated into the DNA, a widespread 
loss of DNA methylation may occur, resulting in genome 
hypomethylation, which may ultimately predispose 
to neoplastic transformation of normal cells [41]. On 
the contrary, hydralazine inhibits DNA methylation by 
establishing highly stable interactions between its nitrogen 
atoms and DNMT active site. Moreover, hydralazine has 
been widely used as an anti-hypertensive agent, orally 
administered on a daily basis for long periods of time 
with minimal secondary effects. Thus, compared to FDA-
approved 5-aza-CdR, hydralazine demonstrates a safer 
profile and might be more attractive for clinical use.
In summary, we showed that the non-nucleoside 
DNMTi hydralazine attenuates the PCa cell phenotype 
by disrupting several cancer cell pathways, in particular 
the EGF pathway in DU145 cells. Moreover, exposure to 
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hydralazine decreased DNMTs expression and induced 
histone acetylation, which might be responsible for re-
expression of genes known to be epigenetically silenced 
in PCa. Interestingly, hydralazine restored AR expression 
in DU145 cells, providing clues to a potential synergistic 
effect with conventional anti-androgenic therapy. In 
vivo studies are now mandatory to further validate the 
promising role of hydralazine in PCa therapy.
MATERIALS AND METHODS
PCa cell lines and drug preparation
PCa cell lines LNCaP and PC-3 were kindly 
provided by Prof. Ragnhild A. Lothe from the Department 
of Cancer Prevention at the Institute for Cancer Research, 
Oslo, Norway, whereas DU145 was kindly provided by 
Professor Fátima Baltazar at ICVS, University of Minho, 
Braga, Portugal and 22Rv1 cells were kindly provided 
by Dr. David Sidransky at the Johns Hopkins University 
School of Medicine, Baltimore, MD, USA. LNCaP and 
22Rv1 cells were grown in RPMI 1640, DU145 cells were 
maintained in MEM and PC-3 cells were grown in 50% 
RPMI-50% F-12 medium (GIBCO, Invitrogen, Carlsbad, 
CA, USA). All basal culture media were supplemented 
with 10% fetal bovine serum and 1% penicillin/
streptomycin (GIBCO, Invitrogen, Carlsbad, CA, USA). 
Cells were maintained in an incubator at 37ºC with 5% 
CO2. All PCa cell lines were karyotyped by G-banding (for 
validation purposes) and routinely tested for Mycoplasma 
spp. contamination (PCR Mycoplasma Detection Set, 
Clontech Laboratories). Hydralazine was purchased from 
Sigma (Sigma-Aldrich, St. Louis, MO, USA) dissolved 
in PBS (GIBCO, Invitrogen, Carlsbad, CA, USA). For 
control purposes, cell lines were exposed to the vehicle of 
the drug (PBS). 
Viability assay
Cell viability was evaluated by MTT assay. Briefly, 
PCa cells were seeded at 5 x 103 cells/mL onto 96-well 
flat bottoned culture plates, allowed to adhere overnight 
and exposed to different Hydralazine concentrations 
(i.e., 20 and 40 µM) for 14 days. At each time point 0.5 
mg/ml of MTT reagent [3-(4, 5dimethylthiazol-2-yl)-2, 
5-diphenyl-tetrazolium bromide] was added to each well, 
and the plates were incubated in the dark for 3 hours at 
37ºC. Formazan crystals were then dissolved in DMSO 
and absorbance was read at 540 nm in a microplate reader 
(FLUOstar Omega, BMG Labtech, Offenburg, Germany), 
subtracting the background, at 630 nm. The number of 
cells was calculated using the formula: [(OD experiment 
x Number of cells at day 0) / Mean OD at day 0]. Three 
replicates were performed for each condition, and at least 
three independent experiments were carried out.
Apoptosis evaluation
Evaluation of apoptosis was performed using 
APOPercentage apoptosis assay kit (Biocolor Ltd., 
Belfast, Northern Ireland) according to the manufacturer’s 
instructions. PCa cells were seeded at 1 x 104 cells/mL 
onto 24-well plates. Apoptotic cells were assessed at 
the end of the day 3, 7 and 14 for LNCaP and 22Rv1, 3 
and 7 for LNCaP and 3 and 14 for PC-3, in a FLUOstar 
Omega microplate reader at 550 nm and the background 
subtracted at 620 nm. The results were normalized to 
number of viable cell obtained in the MTT assay according 
to the following formula (OD of apoptosis assay at day x/ 
OD of MTT at day x).
Cell cycle analysis
Cell cycle distribution of PCa cells was determined 
by flow cytometry. Briefly: 5x105 harvested cells were 
fixed overnight at 4ºC with 70% cold ethanol. After 
washing with cold PBS, cells were ressuspended in 
staining Propidium Iodide Solution (Cytognos S.L, 
Salamanca, Spain) and incubated for 30 minutes at room 
temperature. All cells were then measured on a Cytomics 
FC500 flow cytometer (Beckman Coulter, Fullerton, CA, 
USA) and analyzed using Modfit LT (Verity Software 
House, Inc, Topshan, Maine, USA).
Single Cell Gel Electrophoresis (Comet Assay)
After drug exposure, 50.000 cells were harvested 
by trypsinization, washed in PBS and re-suspended in 75 
μl of low-melting point agarose (Invitrogen, Carlsbad, 
CA, USA).This suspension was then applied on top of 
the base layer consisting of normal-melting point agarose 
in a slide, after which it polymerized for 10 minutes at 
4ºC. The slides were then immersed in lysis solution (2.5 
M NaCl, 100 mM Na2EDTA, 10 mM Tris Base and 1% 
Triton X-100) at 4°C during 2 hours in the dark. To allow 
DNA to unwind, slides were posteriorly incubated in an 
alkaline electrophoresis buffer (300 mM NaOH, 1 mM 
Na2EDTA, pH 13) for 40 minutes at 4ºC. Electrophoresis 
was accomplished on a horizontal electrophoresis platform 
at 4ºC for 20 minutes at 15 V. Next, they were incubated in 
a neutralization buffer (Tris–HCl; pH-7.5) for 10 minutes. 
After fixation with ethanol 100% the slides were stained 
with Sybr Green® (Life Technologies, Foster City, CA, 
USA) and DNA damage was evaluated under a fluorescent 
microscope. At least three independent experiments 
were performed for each condition. The DNA damaging 
effect in terms of DNA fragmentation was determined by 
measuring four parameters that included, tail moment, 
Oncotarget5961www.impactjournals.com/oncotarget
tail length, percentage of DNA in tail of the comet and 
50 DNA-damaged cells were counted at least, for each 
condition. 
Cell Invasion Assay
Cell invasion was determined using BD BioCoat 
Matrigel Invasion Chamber (BD Biosciences, Franklin 
Lakes, NJ, USA). Briefly, 5x104 cel/mL of LNCaP and 
DU145 cells were added to the upper chamber. Both cell 
lines were exposed to 20 and 40 µM of Hydralazine as 
well as to the vehicle for 48 hours, after which the non-
invading cells were removed with cotton swabs from 
the upper side of the membrane. The membrane botton 
containing invading cells was fixed in methanol, washed 
in PBS and stained with DAPI (Vector Laboratories, 
Burlingame, CA). All the invading cells were counted 
under a fluorescent microscope. Three independent 
experiments were performed for each condition, and at 
least two experimental replicates were performed.
Real Time Quantitative PCR (RT-qPCR)
After drug exposure RNA was extracted from cell 
lines using TRIzol® (Invitrogen, Carlsbad, CA, USA) 
according to manufacturer’s instructions. First strand 
synthesis was performed using the high-capacity cDNA 
Reverse Transcription Kit from Applied Biosystems 
(Foster City, CA, USA). Expression of target genes 
(Ki67, CDKN1A, PARP1, APC, RARβ2, GSTP1, CCND2, 
DNMT1, DNMT3a and DNMT3B) was quantified using 
Taqman expression assays, purchased as pre-developed 
assays from Applied Biosystems and normalized to the 
expression of the GUSB housekeeping gene.
Determination of differentially expressed target 
genes by real-time ready arrays
After RNA extraction, 500 ng of total RNA was 
used for cDNA synthesis using the Transcriptor High 
Fidelity cDNA Synthesis Kit (Roche Applied Science) 
according to the manufacturer’s instructions. A 384-well 
custom array panel (Roche Applied Science) was designed 
to quantify the expression of genes involved in multiple 
cellular pathways, namely apoptosis, cell cycle, DNA 
repair and invasion by real-time PCR using a LightCycler 
480 instrument (Roche Diagnostics, Basel, Switzerland). 
The relative expression of target genes was normalized 
using GUSB, TFRC and 18S as housekeeping genes. The 
fold-variation in gene expression was determined using 
comparative Ct method and genes with fold change above 
0.5 or below -0.5 were considered up or downregulated, 
respectively.
Western Blot
Proteins were extracted from whole-cell lysates 
using RIPA lysis buffer (Santa Cruz Biotechnology, 
CA, USA) and subsequently quantified using a Pierce 
BCA assay (Thermo Scientific Inc., Bremen, Germany), 
according to the manufacturer’s instructions. Briefly, 30 
µg of protein from each sample were separated using 
4–20% Mini-PROTEAN® TGX™ Precast Gel at 120 V 
and subsequently blotted onto Protran nitrocellulose 
transfer membranes (Whatman, Dassel, Germany). For 
immunodetection, membranes were incubated overnight 
at 4ºC with antibodies directed against AcH3, AKT 
phosphorylated (S473), C-Jun phosphorylated (S73 and 
Thr91 (Millipore, Billerica, MA), Akt1, SRC (Santa Cruz 
Biotechnology, Santa Cruz, CA) EGFR phosphorylated 
(Y1172) (ProSci Inc., Poway, CA, USA) AR, DNMT1, 
p21 and PARP1 (Cell Signaling Technology, Danvers, 
MA) at 1/500, , EFGR (Kinexus Inc., Vancouver, 
Canada), ERK1/2 (Enzo Life Sciences, Inc., Farmingdale, 
New York) and MEK1 (BD Biosciences, Franklin 
Lakes, NJ, USA) at 1/5000. The Immun-Star WesternC 
Chemiluminescent kit (Bio-Rad, Hercules, CA, USA) 
was used to develop the membranes which were then 
recorded with Amersham Hyperfilm (GE Healthcare 
Buckinghamshire, UK). To ascertain equal loading of 
protein, the membranes were incubated with a monoclonal 
mouse antibody against β-Actin (1:8,000, Sigma-Aldrich, 
CO., St. Louis, MO). Protein band intensities were 
determined using Quantity One software (Bio-Rad), by 
comparing the protein band intensity with the loading 
control (β-Actin). 
Quantitative Methylation Specific PCR (qMSP)
Genomic DNA was extracted from cell lines using a 
standard technique comprising digestion with proteinase K 
(20mg/mL) in the presence of 10% SDS at 55ºC, followed 
by phenol-chloroform extraction and precipitation with 
100% ethanol. One microgram of DNA was submitted 
to bisulfite modification using the EZ DNA Methylation-
Gold™ Kit (Zymo Research, Orange, CA) following 
the manufacturer’s instructions. Bisulfite modified DNA 
was amplified by qMSP using TaqMan technology [42]. 
Specific GSTP1, APC and RARβ2 primers and TaqMan 
probes were designed using the Methyl Primer Express 
Software v1.0 (Applied Biosystems). β-actin (ACTB) was 
used as an internal reference gene to normalize for DNA 
input and all qMSP reactions were performed as previously 
described [11]. Methylation levels for each sample were 
derived from calibration curves constructed using serial 
dilutions of bisulfite modified CpGenomeTM Universal 
Methylated DNA (Millipore, Billerica, MA). GSTP1, 




The Kinex™ KAM-850 antibody microarray 
(Kinexus Inc., Vancouver, Canada) was used to perform 
an unbiased characterization of altered proteins after 
hydralazine exposure. In total, this microarray featured 
854 antibodies of which 517 were pan-specific (for 
protein expression) and 337 were protein phospho-site-
specific (for phosphorylation). Briefly, 50 µg of lysate 
protein from each sample were covalently labeled with a 
fluorescent dye and unincorporated dye molecules were 
removed by ultrafiltration. Purified proteins were then 
incubated on the antibody microarray. After the washing 
steps, the arrays were sent to Kinexus and were scanned 
using a Perkin-Elmer Scan Array Reader (Waltham, MA). 
Signal quantification was performed with ImaGene 8.0 
(BioDiscovery, El Segundo, CA) with predetermined 
settings for spot segmentation and background correction. 
Z ratio analysis was used to identify differentially 
expressed proteins between the vehicle and hydralazine 
treated cells. Three independent replicates were performed 
for each condition. Functional annotation of the identified 
proteins was carried out with the online tool DAVID 
Bioinformatic Resources 2013 (version 6.7) (http://david.
abcc.ncifcrf.gov/).
EGFR Mutational Analysis
The EGFR tyrosine-kinase domain (exons from 18 
to 21) was evaluated for activating mutations in LNCaP, 
22Rv1, DU145 and PC-3 cell lines. High resolution 
melting (HRM) was used as a screening method, after 
which DNA sequencing was performed in all cell lines. 
HRM was performed on a LightCyclerW 480 II Real-
Time System (Roche Diagnostics, Basel, Switzerland). 
PCR mastermix containing one primer pair, all PCR 
reagents, DNA and mineral oil was added to each well 
of a 96 well plate. Amplification and melting curves 
were generated and analyzed using the LightCyclerW 
480 Gene Scanning software version 1.5 (Roche 
diagnostics, Basel, Switzerland.). The generated PCR 
amplification products were subsequently purified using 
illustra GFX PCR DNA and Gel Band Purification Kit 
(GE Healthcare Life Sciences, Little Chalfont, UK) 
according to the manufacturer’s protocol. The sequencing 
reaction was performed using 1 μL of purified PCR 
amplification products, and Big Dye W Terminator 
V1.1 cycle sequencing Ready Reaction Mix (Applied 
Biosystems, Foster City, CA, USA). Sequencing 
PCR products were then purified in order to remove 
contaminants, using illustra SephadexW G-50 fine (GE 
Healthcare Life Sciences, Little Chalfont, UK) and run 
on an ABI PRISM™ 310 Genetic Analyzer. The obtained 
electropherograms were analyzed with Sequencing 
Analysis Software v5.2 (Applied Biosystems, Foster City, 
CA, USA) and read manually.
Statistical analysis
One-way analysis of variance (ANOVA), with post-
hoc Dunnet’s multiple comparison test, when appropriate, 
was used to compare the results obtained in each parameter 
for the two different concentrations of hydralazine and the 
vehicle. Analysis was performed with SPSS software for 
Windows version 19.0 (IBM-SPSS Inc Chigaco, IL) and 
statistical significance was set at p<0.05.
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